Anteris Technologies (AU:AVR) has released an update.
Anteris Technologies Ltd has reported positive advancements in its DurAVR THV technology, including successful patient treatments and favorable feedback from the US FDA on its upcoming pivotal study. The company raised $23 million through a share placement and received an additional $30 million from a capital raise, aiming for FDA study preparation and eventual commercialization. Despite ongoing discussions regarding strategic partnerships and a potential dual NASDAQ/ASX listing, there are no guarantees these will come to fruition.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
